These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 10472348)

  • 41. Tc-99m-MIBI scintimammography; SPECT versus planar imaging.
    Aziz A; Hashmi R; Ogawa Y; Hayashi K
    Cancer Biother Radiopharm; 1999 Dec; 14(6):495-500. PubMed ID: 10850336
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vitro and in vivo study of 99mTc-MIBI encapsulated in PEG-liposomes: a promising radiotracer for tumour imaging.
    Belhaj-Tayeb H; Briane D; Vergote J; Kothan S; Léger G; Bendada SE; Tofighi M; Tamgac F; Cao A; Moretti JL
    Eur J Nucl Med Mol Imaging; 2003 Apr; 30(4):502-9. PubMed ID: 12536243
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dual phase qualitative and quantitative 99mTc-MIBI scintimammography for predicting response to neoadjuvant chemotherapy in breast cancer.
    Zaman MU; Nasir Z; Raza T; Hashmi H; Hashmi A; Fatima N
    J Coll Physicians Surg Pak; 2009 Mar; 19(3):173-8. PubMed ID: 19268018
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tc-99m-methoxy isobutyl isonitrile scintimammography: imaging postexcision biopsy for residual and multifocal breast tumor.
    Usmani S; Khan HA; Niaz K; Uz-Zaman M; Niyaz K; Javed A; al Mohannadi S; Abu al Huda F; Kamal S
    Nucl Med Commun; 2008 Sep; 29(9):826-9. PubMed ID: 18677211
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Scintigraphic detection of breast cancer xenografts with Tc-99m natural and recombinant human alpha-fetoprotein.
    Line BR; Feustel PJ; Festin SM; Andersen TT; Dansereau RN; Lukasiewicz RL; Zhu S; Bennett JA
    Cancer Biother Radiopharm; 1999 Dec; 14(6):485-94. PubMed ID: 10850335
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prediction of chemotherapeutic response by Technetium 99m--MIBI scintigraphy in breast carcinoma patients.
    Takamura Y; Miyoshi Y; Taguchi T; Noguchi S
    Cancer; 2001 Jul; 92(2):232-9. PubMed ID: 11466674
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Contribution of 99mTc-anti-carcinoembryonic antigen antibody and 99mTc-sestamibi scintimammography in the evaluation of high risk palpable breast lesions.
    Sanidas EE; Koukouraki S; Velidaki A; Manios A; Stathopoulos E; De Bree E; Kafousi M; Kodogiannis E; Karkavitsas N; Tsiftsis DD
    Nucl Med Commun; 2003 Mar; 24(3):291-6. PubMed ID: 12612470
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Technetium-99m sestamibi imaging in the detection of axillary lymph node involvement in patients with breast cancer.
    Schillaci O; Scopinaro F; Danieli R; Tavolaro R; Cannas P; Picardi V; Colella AC
    Anticancer Res; 1997; 17(3B):1607-10. PubMed ID: 9179202
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Correlation between uptake of 99Tcm-MIBI and expression of multidrug resistant protein in breast cancer].
    Zhang XM; Zhang ZW; Wu H
    Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):353-5. PubMed ID: 15312346
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tc-99m MIBI uptake in breast carcinoma and axillary lymph node metastases.
    Kao CH; Wang SJ; Yeh SH
    Clin Nucl Med; 1994 Oct; 19(10):898-900. PubMed ID: 7805327
    [TBL] [Abstract][Full Text] [Related]  

  • 51. P-Glycoprotein and multidrug resistance-related protein expressions in relation to technetium-99m methoxyisobutylisonitrile scintimammography findings.
    Kao CH; Tsai SC; Liu TJ; Ho YJ; Wang JJ; Ho ST; ChangLai SP
    Cancer Res; 2001 Feb; 61(4):1412-4. PubMed ID: 11245443
    [TBL] [Abstract][Full Text] [Related]  

  • 52. 99mTc-3P4-RGD2 scintimammography in the assessment of breast lesions: comparative study with 99mTc-MIBI.
    Ma Q; Chen B; Gao S; Ji T; Wen Q; Song Y; Zhu L; Xu Z; Liu L
    PLoS One; 2014; 9(9):e108349. PubMed ID: 25250628
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Residual tumor uptake of [99mTc]-sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survival.
    Dunnwald LK; Gralow JR; Ellis GK; Livingston RB; Linden HM; Lawton TJ; Barlow WE; Schubert EK; Mankoff DA
    Cancer; 2005 Feb; 103(4):680-8. PubMed ID: 15637688
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The role of technetium-99m-labeled octreotide acetate scintigraphy in suspected breast cancer and correlates with expression of SSTR.
    Wang F; Wang Z; Wu J; Qu W; Yao W; Zhao J; Liu Z
    Nucl Med Biol; 2008 Aug; 35(6):665-71. PubMed ID: 18678351
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chest wall recurrence of breast cancer demonstrated on 99mTc-MIBI scintimammography.
    Usmani S; Niaz K; Maseeh-Uz-Zaman ; Niyaz K; Khan HA; Habib S; Kamal S
    Nucl Med Commun; 2007 Nov; 28(11):842-6. PubMed ID: 17901766
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Predictive value of bone marrow accumulation of Tc-99m tetrofosmin for subsequent development of distant metastases in breast cancer.
    Wakasugi S; Tsukuma H; Inaji H; Hashizume T; Noguchi A; Ohnishi T
    Ann Nucl Med; 2007 Oct; 21(8):429-37. PubMed ID: 17952551
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Correlation between accumulation of (99m)Tc-MIBI in breast cancer or benign lesion, cell proliferation and angiogenesis].
    Chen J; Yin Y; Chen S
    Zhonghua Wai Ke Za Zhi; 1998 Sep; 36(9):553-5. PubMed ID: 11825464
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Technetium-99m-tetrofosmin in diagnosis of breast cancer and axillary lymph node involvement.
    Jaukovic LDj; Ajdinovic BZ; Jankovic ZD; Strbac M
    Nucl Med Rev Cent East Eur; 2006; 9(1):30-6. PubMed ID: 16791801
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic value of (99m)Tc-sestamibi washout in predicting response of locally advanced breast cancer to neoadjuvant chemotherapy.
    Sciuto R; Pasqualoni R; Bergomi S; Petrilli G; Vici P; Belli F; Botti C; Mottolese M; Maini CL
    J Nucl Med; 2002 Jun; 43(6):745-51. PubMed ID: 12050317
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive.
    Van Calster B; Vanden Bempt I; Drijkoningen M; Pochet N; Cheng J; Van Huffel S; Hendrickx W; Decock J; Huang HJ; Leunen K; Amant F; Berteloot P; Paridaens R; Wildiers H; Van Limbergen E; Weltens C; Timmerman D; Van Gorp T; Smeets A; Van den Bogaert W; Vergote I; Christiaens MR; Neven P
    Breast Cancer Res Treat; 2009 Jan; 113(1):181-7. PubMed ID: 18264760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.